Lv11
50 积分 2024-01-08 加入
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
4小时前
待确认
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
9天前
已完结
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
2个月前
已完结
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
2个月前
已完结
Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study
4个月前
已完结
Patients' Preferences for Adjuvant Osimertinib in Non-Small Cell Lung Cancer After Complete Surgical Resection: What makes it worth it to Patients?
6个月前
已完结
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
7个月前
已完结
皖公网安备34019202002308
